Latest From Ipsen
Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.
The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Beaufour Ipsen
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Senior Management
David Meek, CEO
Aymeric Le Chatelier, EVP, Fin. & CFO
Alexandre Lebeaut, MD, EVP, R&D & CSO
Ivana Magovcevic-Liebisch, EVP, CBO
- Contact Info
Phone: (33) 1 58 33 50 00
65 Quai George Gorse
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.